Advanced glycation end products and their receptors in serum of patients with type 2 diabetes

Abstract Glycation is a non-enzymatic process involving the reaction of reducing sugars or reactive oxoaldehyde with proteins, lipids or nucleic acids, which results in the formation of advanced glycation end products (AGEs). The presented work discusses the glycation process in people with advanced...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diana Indyk, Agnieszka Bronowicka-Szydełko, Andrzej Gamian, Aleksandra Kuzan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/28fe6f922a48497f9a0698bb45ec8f3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28fe6f922a48497f9a0698bb45ec8f3d
record_format	dspace
spelling	oai:doaj.org-article:28fe6f922a48497f9a0698bb45ec8f3d2021-12-02T17:12:21ZAdvanced glycation end products and their receptors in serum of patients with type 2 diabetes10.1038/s41598-021-92630-02045-2322https://doaj.org/article/28fe6f922a48497f9a0698bb45ec8f3d2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92630-0https://doaj.org/toc/2045-2322Abstract Glycation is a non-enzymatic process involving the reaction of reducing sugars or reactive oxoaldehyde with proteins, lipids or nucleic acids, which results in the formation of advanced glycation end products (AGEs). The presented work discusses the glycation process in people with advanced stage of type 1 or type 2 diabetes. The concentration of different AGEs and their receptors for 58 serum samples was determined by ELISA and by spectrofluorimetric methods. In addition to fluorescent low molecular weight and protein-bound AGEs, we have also marked a new class of AGEs: melibiose-derived glycation product (MAGE). Our attention was also focused on the two groups of AGEs receptors: scavenger receptors (SR-A and SR-B) and RAGE. The correlation between the SR-AI scavenging receptors concentration and the fluorescence of AGEs as well as diabetes biological markers: GFR, creatinine contentration and HbA1c was demonstrated. A relationship between the concentration of AGEs and their receptors was also found in serum sample of patients treated with the metformin and aspirin. Furthermore, the concentration of SR-AI scavenger and the fluorescence of total AGEs was significantly lower in treated patients than in non treated patients. AGEs have also been found to contribute to the development of cardiovascular disease, atherosclerosis and diabetic complications, what could be deduced from the correlation of AGEs level and HDL cholesterol or uric acid level. Thus, it was confirmed that AGEs are involved in the pathomechanism of diabetes and other degenerative diseases. Nowadays, it is believed that AGEs due to the long time remaining in the body may be an important diagnostic marker. Their determination may allow monitoring the progression of the disease and the effectiveness of the therapy.Diana IndykAgnieszka Bronowicka-SzydełkoAndrzej GamianAleksandra KuzanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Diana Indyk Agnieszka Bronowicka-Szydełko Andrzej Gamian Aleksandra Kuzan Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
description	Abstract Glycation is a non-enzymatic process involving the reaction of reducing sugars or reactive oxoaldehyde with proteins, lipids or nucleic acids, which results in the formation of advanced glycation end products (AGEs). The presented work discusses the glycation process in people with advanced stage of type 1 or type 2 diabetes. The concentration of different AGEs and their receptors for 58 serum samples was determined by ELISA and by spectrofluorimetric methods. In addition to fluorescent low molecular weight and protein-bound AGEs, we have also marked a new class of AGEs: melibiose-derived glycation product (MAGE). Our attention was also focused on the two groups of AGEs receptors: scavenger receptors (SR-A and SR-B) and RAGE. The correlation between the SR-AI scavenging receptors concentration and the fluorescence of AGEs as well as diabetes biological markers: GFR, creatinine contentration and HbA1c was demonstrated. A relationship between the concentration of AGEs and their receptors was also found in serum sample of patients treated with the metformin and aspirin. Furthermore, the concentration of SR-AI scavenger and the fluorescence of total AGEs was significantly lower in treated patients than in non treated patients. AGEs have also been found to contribute to the development of cardiovascular disease, atherosclerosis and diabetic complications, what could be deduced from the correlation of AGEs level and HDL cholesterol or uric acid level. Thus, it was confirmed that AGEs are involved in the pathomechanism of diabetes and other degenerative diseases. Nowadays, it is believed that AGEs due to the long time remaining in the body may be an important diagnostic marker. Their determination may allow monitoring the progression of the disease and the effectiveness of the therapy.
format	article
author	Diana Indyk Agnieszka Bronowicka-Szydełko Andrzej Gamian Aleksandra Kuzan
author_facet	Diana Indyk Agnieszka Bronowicka-Szydełko Andrzej Gamian Aleksandra Kuzan
author_sort	Diana Indyk
title	Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
title_short	Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
title_full	Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
title_fullStr	Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
title_full_unstemmed	Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
title_sort	advanced glycation end products and their receptors in serum of patients with type 2 diabetes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/28fe6f922a48497f9a0698bb45ec8f3d
work_keys_str_mv	AT dianaindyk advancedglycationendproductsandtheirreceptorsinserumofpatientswithtype2diabetes AT agnieszkabronowickaszydełko advancedglycationendproductsandtheirreceptorsinserumofpatientswithtype2diabetes AT andrzejgamian advancedglycationendproductsandtheirreceptorsinserumofpatientswithtype2diabetes AT aleksandrakuzan advancedglycationendproductsandtheirreceptorsinserumofpatientswithtype2diabetes
_version_	1718381425463394304

Advanced glycation end products and their receptors in serum of patients with type 2 diabetes

Ejemplares similares